Medical sources · Research library

Credible links,
not citation theater.

The source library behind The Glow Diary’s GLP-1, peptide, safety, and pipeline coverage. We prioritize primary research, regulatory labels, government health references, and transparent review dates.

Regulatory and labels

FDA drug labelsOfficial prescribing labels and approval information.FDA concerns with unapproved GLP-1 drugsConsumer/provider safety concerns for unapproved GLP-1 products.openFDA drug label APIProgrammatic access to drug label data.

Clinical trial and research anchors

PubMedPrimary search layer for biomedical literature.ClinicalTrials.govTrial registry for investigational and approved therapies.STEP 1 semaglutide trialSemaglutide obesity trial abstract.SURMOUNT-1 tirzepatide trialTirzepatide obesity trial abstract.Retatrutide phase 2 trialInvestigational triple agonist trial abstract.

Pipeline watchlist searches

Orforglipron literatureOral small-molecule GLP-1 evidence trail.Amycretin literatureAmylin-plus-GLP-1 research watchlist.CagriSema trialsCombination GLP-1/amylin trial registry.Mazdutide literatureDual GLP-1/glucagon metabolic pipeline trail.Survodutide literatureObesity and MASH crossover search.Pemvidutide literatureMetabolic-liver pipeline watchlist.

Patient-friendly government references

NIDDK weight-management medicinesGovernment overview of prescription medication options.MedlinePlus semaglutideMedication information for patients.MedlinePlus tirzepatideMedication information for patients.

How to read our links

PubMed abstracts, FDA labels, and government health pages are stronger anchors than clinic blogs, influencer protocols, or press releases.

What source links do not mean

A link proves traceability, not personalized fit. Trial populations, indications, dose, and exclusions all matter.

Corrections welcome

If a source changes or a link breaks, send it through the contact page so we can update the review trail.

Credible links,not citation theater.